Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More <i>F508del</i> Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

Authors: Matthias Griese, Stefano Costa, Rachel W. Linnemann, Marcus A. Mall, Edward F. McKone, Deepika Polineni, Bradley S. Quon, Felix C. Ringshausen, Jennifer L. Taylor-Cousar, Nicholas J. Withers, Samuel M. Moskowitz, Cori L. Daines

Published: 2020-09-24

DOI: 10.1164/rccm.202008-3176le

Source: Full article

---

Abstract

No abstract found.